|
|
 |
|
Viewing report
|
|
|
Vertex's VX770 Is Poised To Become The First Targeted Therapy To Be Approved In Cystic Fibrosis
GlobalData, March 2011, Pages: 4
Vertex’s VX770 Is Poised To Become The First Targeted Therapy To Be Approved In Cystic Fibrosis
Summary
Our report, “Vertex’s VX770 Is Poised To Become The First Targeted Therapy To Be Approved In Cystic Fibrosis” provides key information on current available treatment of Cystic Fibrosis and importance Vertex’s VX770 as a target therapy in Cystic Fibrosis market.
Scope
- Data and information on role of newer VEGF Inhibitors in Cystic Fibrosis
Reasons to buy
- Develop business strategies by understanding the trends and developments in Cystic Fibrosis Market
|
|
|
|
